当前位置: X-MOL 学术J. Clin. Invest. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Personal tumor antigens in blood malignancies: genomics-directed identification and targeting.
The Journal of Clinical Investigation ( IF 15.9 ) Pub Date : 2020-01-27 , DOI: 10.1172/jci129209
Livius Penter 1, 2 , Catherine J Wu 2, 3, 4, 5
Affiliation  

Hematological malignancies have long been at the forefront of the development of novel immune-based treatment strategies. The earliest successful efforts originated from the extensive body of work in the field of allogeneic hematopoietic stem cell transplantation. These efforts laid the foundation for the recent exciting era of cancer immunotherapy, which includes immune checkpoint blockade, personal neoantigen vaccines, and adoptive T cell transfer. At the heart of the specificity of these novel strategies is the recognition of target antigens presented by malignant cells to T cells. Here, we review the advances in systematic identification of minor histocompatibility antigens and neoantigens arising from personal somatic alterations or recurrent driver mutations. These exciting efforts pave the path for the implementation of personalized combinatorial cancer therapy.

中文翻译:

血液恶性肿瘤中的个人肿瘤抗原:基因组学指导的鉴定和靶向。

长期以来,血液恶性肿瘤一直处于以免疫为基础的新型治疗策略的发展前沿。最早的成功努力源自同种异体造血干细胞移植领域的广泛工作。这些努力为近期的癌症免疫疗法激动人心的时代奠定了基础,其中包括免疫检查点封锁,个人新抗原疫苗和过继性T细胞转移。这些新策略的特异性的核心是识别恶性细胞对T细胞呈递的靶抗原。在这里,我们综述了系统识别由个体体细胞改变或复发性驱动基因突变引起的次要组织相容性抗原和新抗原的进展。
更新日期:2020-04-03
down
wechat
bug